Long-acting Exenatide: a Tool to Stop Cognitive Decline in Dysglycemic Patients With Mild Cognitive Impairment?

Trial Profile

Long-acting Exenatide: a Tool to Stop Cognitive Decline in Dysglycemic Patients With Mild Cognitive Impairment?

Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2016

At a glance

  • Drugs Exenatide (Primary)
  • Indications Mild cognitive impairment; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms DRINN
  • Most Recent Events

    • 01 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top